Biostem Tech Stock Price, News & Analysis

BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived advanced wound care products, has appointed Brandon Poe as its new Chief Financial Officer. Poe, who has served on BioStem's Board since 2022, brings over 25 years of healthcare and life sciences experience, including senior finance roles at Midi Health, Jumpcode Genomics, and Illumina.

The appointment comes at a strategic time as BioStem pursues market expansion and Nasdaq uplisting plans. The former CFO, Michael Fortunato, will transition to the role of Chief Accounting Officer. Poe's extensive background in capital markets and operational excellence, combined with his familiarity with BioStem's business, positions him to support the company's growth initiatives and BioREtain® platform development.

BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived products for advanced wound care, will release its Q2 2025 financial results on August 14, 2025, followed by a conference call at 4:30 PM ET.

The conference call will feature CEO Jason Matuszewski and CFO Michael Fortunato discussing quarterly results and providing updates on the company's Form 10 filing and planned Nasdaq uplisting. The company's core business focuses on manufacturing allografts using their proprietary BioREtain® processing method, with products including AmnioWrap2™, VENDAJE®, and American Amnion™.

BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived wound care products, has responded to CMS's proposed changes for skin substitute reimbursement in CY 2026. The company supports the reform efforts aimed at addressing Medicare spending in this category.

CEO Jason Matuszewski emphasized their commitment to working with stakeholders during the 60-day comment period to optimize reimbursement methodology. The company is conducting randomized controlled trials (RCTs) for their BioREtain® technology across multiple indications, with initial results expected later this year.

Additionally, BioStem is progressing with its Form 10 filing and plans to provide updates on its Nasdaq uplisting during Q2 2025 earnings call.

BioStem Technologies (OTC: BSEM), a leading MedTech company specializing in placental-derived products for advanced wound care, announces that Chairman and CEO Jason Matuszewski will present at the Advanced Wound Care Summit's Investor Forum on July 15, 2025, at 2:00 PM ET in Boston.

The presentation, titled "Invest in the Future of Advanced Wound Care with BioStem Technologies," will showcase the company's core allograft business and growth opportunities. BioStem leverages its proprietary BioREtain® processing method and maintains AATB accreditation and FDA registration for its Pompano Beach facility. The company's portfolio includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, VENDAJE OPTIC®, American Amnion and American Amnion AC.

BioStem Technologies (OTC: BSEM) has completed enrollment of 71 patients in its clinical trial evaluating BioREtain Amnion Chorion (BR-AC) for treating diabetic foot ulcers (DFUs). The multicenter, randomized controlled trial, initiated in Q4 2024 across 11 U.S. sites, aims to demonstrate superior wound healing compared to standard care over 12 weeks. Topline results are expected in Q4 2025. The study is part of three ongoing clinical trials for BioREtain-processed allografts. The DFU market represents a significant opportunity, with 2.2 million patients treated in 2023 and annual treatment costs between $9-13 billion in the U.S. According to APMA, approximately 15% of diabetic patients develop foot ulcers, with 14-24% potentially requiring amputation.

Ernst & Young LLP (EY US) has named Jason Matuszewski, CEO and Chairman of BioStem Technologies (OTC: BSEM), as an Entrepreneur Of The Year 2025 Florida Award winner. BioStem Technologies, based in Pompano Beach, Florida, is a MedTech company specializing in placental-derived allografts using their proprietary BioREtain technology for chronic wound care. The company develops and manufactures advanced wound care solutions used by clinicians nationwide. As a Florida award winner, Matuszewski advances to consideration for the National Awards at the Strategic Growth Forum in November 2025, with potential advancement to the EY World Entrepreneur Of The Year Award competition in June 2026.

BioStem Technologies (OTC: BSEM) has provided an update on its Form 10 registration statement and SEC review process. The company anticipates filing an amended Form 10 by end of June 2025, which will include audited financials for 2023-2024 and Q1 2025 unaudited results. BioStem believes it has successfully addressed SEC's accounting comments regarding revenue treatment and fees paid to Venture Medical. The company has submitted its Nasdaq listing application and plans to uplist upon Form 10 effectiveness. BioStem Technologies specializes in developing and manufacturing placental-derived products for advanced wound care using its proprietary BioREtain processing method. The company maintains AATB accreditation and FDA registration for its Pompano Beach facility.

BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived products for advanced wound care, announces its participation in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami. CEO Jason Matuszewski will engage in a fireside chat and one-on-one meetings.

BioStem Technologies leverages its proprietary BioREtain® processing method to develop and manufacture allografts. The company's portfolio includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC® products. Their facility in Pompano Beach, Florida, is FDA registered and AATB accredited, operating under cGTP and cGMP standards.

BioStem Technologies (OTC: BSEM) has received Notice of Allowance from the USPTO for three new patents - two design patents and one utility patent - related to their fenestrated human placental allograft designs and compositions. The patents cover their novel BioREtain® process and unique fenestration design that allows wound exudate to pass through the graft while maintaining allograft area. This technology preserves the structural and molecular integrity of amnion and chorion tissues, enhancing wound treatment particularly for diabetic foot ulcers and dental wounds. The company's expanding patent portfolio now includes 55 issued patents and 52 pending applications. BioStem's quality management system is accredited by the American Association of Tissue Banks (AATB), and their products are processed at their FDA registered facility in Pompano Beach, Florida.